Drug-drug interaction profiles of proton pump inhibitors (Q37770556)

22 August 2017

1 reference

title

Drug-drug interaction profiles of proton pump inhibitors (English)

1 reference

22 August 2017

0 references

Ryuichi Ogawa

1

1 reference

22 August 2017

Hirotoshi Echizen

series ordinal

2

1 reference

22 August 2017

publication date

1 August 2010

1 reference

Clinical Pharmacokinetics

22 August 2017

published in

1 reference

22 August 2017

volume

49

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

509-533

1 reference

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Influence of gastric acidity on the bioavailability of digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Omeprazole: effects on oxidative drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Oral phenytoin pharmacokinetics during omeprazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

No influence of single intravenous doses of omeprazole on theophylline elimination kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

A study of the interaction of omeprazole and warfarin in anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

The effect of antacids and metoclopramide on omeprazole absorption and disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Influence of lansoprazole treatment on diazepam plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531320-000000000-00000

Pharmacokinetic profile of 14C-labeled clopidogrel

21 January 2018

1 reference

12 December 2020

Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication

1 reference

12 December 2020

Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

1 reference

12 December 2020

Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.

1 reference

12 December 2020

Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.

1 reference

12 December 2020

Transmucosal penetration of bismuth particles in the human stomach

1 reference

12 December 2020

Interethnic difference in omeprazole's inhibition of diazepam metabolism*

1 reference

12 December 2020

The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole

1 reference

12 December 2020

Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration

1 reference

12 December 2020

Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia

1 reference

12 December 2020

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

1 reference

12 December 2020

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome

1 reference

12 December 2020

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma

1 reference

12 December 2020

Acid suppression by omeprazole does not affect orally administered metronidazole bioavailability and metabolism in healthy male volunteers

1 reference

12 December 2020

Pharmacokinetic interaction between acetaminophen and lansoprazole

1 reference

12 December 2020

Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole

1 reference

12 December 2020

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes

1 reference

12 December 2020

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

1 reference

12 December 2020

Omeprazole-associated digoxin toxicity

1 reference

12 December 2020

Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms

1 reference

12 December 2020

The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients

1 reference

12 December 2020

Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers

1 reference

12 December 2020

Omeprazole treatment does not affect the metabolism of caffeine

1 reference

12 December 2020

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

1 reference

12 December 2020

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

12 December 2020

Pantoprazole does not interact with the pharmacokinetics of carbamazepine

1 reference

12 December 2020

Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline

1 reference

12 December 2020

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

1 reference

12 December 2020

More about omeprazole-cyclosporine interaction

1 reference

12 December 2020

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

12 December 2020

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin

1 reference

12 December 2020

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.

1 reference

12 December 2020

Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status

1 reference

12 December 2020

Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

1 reference

12 December 2020

Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments

1 reference

12 December 2020

The effect of oral omeprazole on the disposition of lignocaine.

1 reference

12 December 2020

Artemisinin induces omeprazole metabolism in human beings

1 reference

12 December 2020

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

1 reference

12 December 2020

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

1 reference

12 December 2020

Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations

1 reference

12 December 2020

Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.

1 reference

12 December 2020

Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.

1 reference

12 December 2020

Pharmacokinetic interaction between lansoprazole and theophylline

1 reference

12 December 2020

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of itraconazole

1 reference

12 December 2020

Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules

1 reference

12 December 2020

Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability

1 reference

12 December 2020

Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline

1 reference

12 December 2020

CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies

1 reference

12 December 2020

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

1 reference

12 December 2020

Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis?

1 reference

12 December 2020

Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers

1 reference

12 December 2020

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine

1 reference

12 December 2020

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial

1 reference

12 December 2020

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant

1 reference

12 December 2020

Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole

1 reference

12 December 2020

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

1 reference

12 December 2020

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers

1 reference

12 December 2020

Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors

1 reference

12 December 2020

Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole

1 reference

12 December 2020

Pharmacology of proton pump inhibitors

1 reference

12 December 2020

No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions

1 reference

12 December 2020

Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults

1 reference

12 December 2020

Identification and biological activity of the active metabolite of clopidogrel

1 reference

12 December 2020

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

1 reference

12 December 2020

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

1 reference

12 December 2020

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction

1 reference

12 December 2020

Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers

1 reference

12 December 2020

Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects

1 reference

12 December 2020

Stereoselective disposition of proton pump inhibitors

1 reference

12 December 2020

Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol

1 reference

12 December 2020

Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient

1 reference

12 December 2020

Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation

1 reference

12 December 2020

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

1 reference

12 December 2020

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

1 reference

12 December 2020

Pharmacokinetics of clopidogrel

1 reference

12 December 2020

Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone

1 reference

12 December 2020

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study

1 reference

12 December 2020

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir

1 reference

12 December 2020

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

1 reference

12 December 2020

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

12 December 2020

Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism

1 reference

12 December 2020

Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.

1 reference

12 December 2020

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

1 reference

12 December 2020

Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes

1 reference

12 December 2020

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers

1 reference

12 December 2020

Pharmacokinetic drug interaction profiles of proton pump inhibitors

1 reference

12 December 2020

Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?

1 reference

12 December 2020

Pantoprazole lacks induction of CYP1A2 activity in man

1 reference

12 December 2020

Interactions between protease inhibitors and acid-reducing agents: a systematic review.

1 reference

12 December 2020

Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients

1 reference

12 December 2020

Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

1 reference

12 December 2020

Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers

1 reference

12 December 2020

Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor

1 reference

12 December 2020

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19

1 reference

12 December 2020

Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders

1 reference

12 December 2020

Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report

1 reference

12 December 2020

Potential interaction between methotrexate and omeprazole

1 reference

12 December 2020

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

1 reference

12 December 2020

Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation

1 reference

12 December 2020

Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects

1 reference

12 December 2020

Effect of omeprazole on the metabolism of cilostazol

1 reference

12 December 2020

The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects

1 reference

12 December 2020

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man

1 reference

12 December 2020

Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers

1 reference

12 December 2020

A study of the interaction between omeprazole and phenytoin in epileptic patients

1 reference

12 December 2020

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes

1 reference

12 December 2020

Effect of pH on disintegration and dissolution of ketoconazole tablets

1 reference

12 December 2020

A study of the interaction between omeprazole and cyclosporine in renal transplant patients

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers.

1 reference

12 December 2020

Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

1 reference

12 December 2020

Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.

1 reference

12 December 2020

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir

1 reference

12 December 2020

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

1 reference

12 December 2020

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

12 December 2020

Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19

1 reference

12 December 2020

Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation

1 reference

12 December 2020

Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

1 reference

12 December 2020

Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy.

1 reference

12 December 2020

Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics

1 reference

12 December 2020

Omeprazole-cyclosporin interaction

1 reference

12 December 2020

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

1 reference

12 December 2020

Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies

1 reference

12 December 2020

Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole

1 reference

12 December 2020

Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers

1 reference

12 December 2020

Propranolol steady-state pharmacokinetics are unaltered by omeprazole

1 reference

12 December 2020

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status

1 reference

12 December 2020

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data

1 reference

12 December 2020

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

1 reference

12 December 2020

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

1 reference

12 December 2020

Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient

1 reference

12 December 2020

Theophylline steady state pharmacokinetics is not altered by omeprazole

1 reference

12 December 2020

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently

1 reference

12 December 2020

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

12 December 2020

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

1 reference

12 December 2020

The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole

1 reference

12 December 2020

Effects of lansoprazole on pharmacokinetics and metabolism of theophylline

1 reference

12 December 2020

Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers.

1 reference

12 December 2020

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

12 December 2020

Drug interactions with proton pump inhibitors

1 reference

12 December 2020

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

1 reference

12 December 2020

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction

1 reference

12 December 2020

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.

1 reference

12 December 2020

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.

1 reference

12 December 2020

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

1 reference

12 December 2020

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers

1 reference

12 December 2020

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

1 reference

12 December 2020

Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers

1 reference

12 December 2020

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man

1 reference

12 December 2020

Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment

1 reference

12 December 2020

Stereoselective interaction of omeprazole with warfarin in healthy men

1 reference

12 December 2020

Effect of omeprazole and cimetidine on plasma diazepam levels.

1 reference

12 December 2020

Pantoprazole does not interact with nifedipine in man under steady-state conditions

1 reference

12 December 2020

Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

1 reference

12 December 2020

Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism

1 reference

12 December 2020

A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin

1 reference

12 December 2020

Effects of omeprazole on plasma levels of raltegravir

1 reference

12 December 2020

Drug metabolism and variability among patients in drug response

1 reference

12 December 2020

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

1 reference

12 December 2020

Does interaction between omeprazole and cyclosporin exist?

1 reference

12 December 2020

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate

1 reference

12 December 2020

Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin

1 reference

12 December 2020

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

1 reference

12 December 2020

No influence of pantoprazole on the pharmacokinetics of phenytoin

1 reference

12 December 2020

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

1 reference

12 December 2020

Lack of pharmacokinetic interaction between pantoprazole and diclofenac

1 reference

12 December 2020

Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients.

1 reference

12 December 2020

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*

1 reference

12 December 2020

Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

1 reference

12 December 2020

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

12 December 2020

Influence of omeprazole on pharmacokinetics of domperidone given as free base and maleate salt in healthy Chinese patients

1 reference

12 December 2020

Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole

1 reference

12 December 2020

A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate

1 reference

12 December 2020

Specific and dose-dependent enzyme induction by omeprazole in human beings.

1 reference

12 December 2020

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

1 reference

12 December 2020

New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review

1 reference

12 December 2020

Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.

1 reference

12 December 2020

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers

1 reference

12 December 2020

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers

1 reference

12 December 2020

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models

1 reference

12 December 2020

10.2165/11531320-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1018368775

0 references

1 reference